Oxford Biomedica plc

OXB

GB00BDFBVT43

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:04 2024-05-20 am EDT			5-day change	1st Jan Change
326 ^GBX	+0.77%		+2.68%	+48.18%

May. 09	Avon Protection wins UK MoD supply deal; Molten Ventures up	AN
May. 09	Molten Ventures wins UK MoD supply contract	AN

Oxford Biomedica plc Provides Revenue Guidance for the Second Half of 2021

September 22, 2021 at 07:00 am EDT

Oxford Biomedica plc provided revenue guidance for the second half of 2021. For the half, the company expects revenue for the second half to be similar to the first half.

Latest news about Oxford Biomedica plc

Avon Protection wins UK MoD supply deal; Molten Ventures up	May. 09	AN
Molten Ventures wins UK MoD supply contract	May. 09	AN
NatWest target raised, other lenders backed	May. 09	AN
Jefferies cuts AJ Bell; Deutsche likes ConvaTec	May. 03	AN
FTSE 100 as investors look to Fed rate decision	Apr. 29	AN
Transcript : Oxford Biomedica plc, Q4 2023 Earnings Call, Apr 29, 2024	Apr. 29
Oxford BioMedica bullish; Petrofac slumps	Apr. 29	AN
Earnings Flash (OXB.L) OXFORD BIOMEDICA Reports FY23 Revenue GBP89.5M	Apr. 29	MT
Oxford Biomedica plc Reiterates Earnings Guidance for the Year 2024	Apr. 29	CI
Oxford Biomedica plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Stifel Upgrades Oxford BioMedica to Buy from Hold, Lifts PT	Apr. 18	MT
HSBC likes Haleon, cuts Flutter to 'hold'	Apr. 18	AN
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake	Mar. 20	AN
Oxford Biomedica Secures New Deal, Expands Existing Agreements for Clinical Programs	Mar. 20	MT
Oxford Biomedica plc Announces Board Changes	Mar. 11	CI
EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract	Mar. 05	AN
Oxford Biomedica plc Provides Earnings Guidance for the Year Ended December 31, 2023 and for the Fiscal Year 2024	Mar. 05	CI
Barclays cuts Bank of Ireland to 'equal weight'	Mar. 05	AN
EnSilica hires new chief financial officer from Oxford Biomedica	Feb. 05	AN
EnSilica Appoints Oxford Biomedica Executive as CFO	Feb. 05	MT
Oxford Biomedica Completes EUR15 Million ABL Europe Acquisition	Jan. 29	MT
Institut Merieux ups stake in Oxford BioMedica toward 10%	Jan. 29	AN
Oxford Biomedica plc completed the acquisition of additional 3.2% stake in ABL EUROPE S.A.S. from TSGH ?6.1 million	Jan. 28	CI
Transcript : Oxford Biomedica plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024	Jan. 09
Oxford BioMedica posts optimistic outlook on uptick in contract value	Dec. 07	AN

Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.

Sector

Biotechnology & Medical Research

Calendar

2024-06-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Oxford Biomedica plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.26 GBP

Average target price

4.304 GBP

Spread / Average Target

+32.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OXFORD BIOMEDICA PLC	+48.18%	414M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
ARGENX SE	-2.59%	21.6B
BIONTECH SE	-12.38%	22.31B
GENMAB A/S	-5.29%	19.19B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B

Bio Therapeutic Drugs